Erika Hamilton, Chief Development Officer, Late Phase and Director of the Breast Cancer Research Program at Sarah Cannon Research Institute, shared on LinkedIn:
“I’m always a big fan of plain language summaries of clinical trials. It’s an exciting time to be in oncology because our patients are often such savvy consumers of trial data. Plain language summaries can help them digest the trial data directly, decide what is right for them, and have a list of questions to discuss with their care team – and frankly, are nicer to look at!
Plain language summary linked for the HER2CLIMB05 manuscript – this trial looked at adding tucatinib to pertuzumab and trastuzumab maintenance therapy for patients w/ 1st line HER2+ mBC.”
Title: Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05
Authors: Véronique Diéras, Giuseppe Curigliano, Miguel Martín, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J. Jerzak, Xichun Hu, Luciana Carla Martins de Aquino Pimentel, Ciara C. O’Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Muelle, Shan Yang, Giovanna Granata, Qi Shen, Erika Hamilton.
Continue exploring:
